Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Causal inference for definitive clinical end points in a randomized clinical trial with intervening nonrandomized treatments.

Korn EL, Freidlin B.

J Clin Oncol. 2010 Aug 20;28(24):3800-2. doi: 10.1200/JCO.2010.30.0442. Epub 2010 Jul 26. No abstract available.

2.

Improving the design of phase II trials of cytostatic anticancer agents.

Stone A, Wheeler C, Barge A.

Contemp Clin Trials. 2007 Feb;28(2):138-45. Epub 2006 Jul 14. Review.

PMID:
16843736
4.
5.

Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia.

Herbst C, Monsef I, Skötz N, Engert A; Cochrane Haematological Malignancies Group.

J Natl Cancer Inst. 2008 Aug 6;100(15):E1. doi: 10.1093/jnci/djn212. Epub 2008 Jul 29. Review. No abstract available.

6.

[Current strategies in the treatment of advanced stage mantle cell lymphoma].

Lenz G, Dreyling M, Unterhalt M, Hiddemann W.

Dtsch Med Wochenschr. 2004 Nov 5;129(45):2429-33. Review. German.

PMID:
15529247
7.

Causality in complex interventions.

Rickles D.

Med Health Care Philos. 2009 Mar;12(1):77-90. doi: 10.1007/s11019-008-9140-4. Epub 2008 May 9. Review.

PMID:
18465202
8.

Survival end point reporting in randomized cancer clinical trials: a review of major journals.

Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A.

J Clin Oncol. 2008 Aug 1;26(22):3721-6. doi: 10.1200/JCO.2007.14.1192. Review.

PMID:
18669458
9.

Retinoid therapy of high-risk neuroblastoma.

Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ.

Cancer Lett. 2003 Jul 18;197(1-2):185-92. Review.

PMID:
12880980
10.

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

Mocellin S, Pasquali S, Rossi CR, Nitti D.

J Natl Cancer Inst. 2010 Apr 7;102(7):493-501. doi: 10.1093/jnci/djq009. Epub 2010 Feb 23. Review.

11.

Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.

Suman VJ, Dueck A, Sargent DJ.

Cancer Invest. 2008 Jun;26(5):439-44. doi: 10.1080/07357900801971057. Review. No abstract available.

PMID:
18568764
12.

A comparison of current neuroblastoma chemotherapeutics.

Castel V, Cañete A.

Expert Opin Pharmacother. 2004 Jan;5(1):71-80. Review.

PMID:
14680437
13.

Role of autologous stem cell transplantation in multiple myeloma.

Kumar S.

Curr Hematol Malig Rep. 2007 May;2(2):121-7. doi: 10.1007/s11899-007-0017-z. Review.

PMID:
20425360
14.
15.

A systematic overview of chemotherapy effects in acute myeloid leukaemia.

Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):231-52. Review.

PMID:
11441935
16.

Status of high-dose chemotherapy for breast cancer: a review.

Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF.

Biol Blood Marrow Transplant. 2000;6(5):476-95. Review.

PMID:
11063377
17.

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM.

J Clin Oncol. 2008 Aug 1;26(22):3791-6. doi: 10.1200/JCO.2008.16.1711. Review. Erratum in: J Clin Oncol. 2009 Apr 20;27(12):2109-10.

18.

Other paradigms: randomized discontinuation trial design.

Stadler W.

Cancer J. 2009 Sep-Oct;15(5):431-4. doi: 10.1097/PPO.0b013e3181bd0431. Review.

PMID:
19826364
19.

Autologous hematopoietic stem cell transplantation for pediatric solid tumors.

Hale GA.

Expert Rev Anticancer Ther. 2005 Oct;5(5):835-46. Review.

PMID:
16221053
20.

Autologous hematopoietic cell transplantation in Hodgkin's disease.

Johnston LJ, Horning SJ.

Biol Blood Marrow Transplant. 2000;6(3A):289-300. Review.

PMID:
10905766
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk